Dr Peter McCullough: Prescription and Over-the-Counter Treatments for Long COVID Syndrome (2023)
Get link
Facebook
X
Pinterest
Email
Other Apps
By
Editorial Team
-
Over three years into the pandemic with nearly the entire country having become
sick with SARS-CoV-2, a virus engineered to invade the body, there are millions
suffering with long-hauler syndrome. Approximately half of patients admitted to
the ICU with COVID-19 will have post-COVID syndrome which is now understood to
be due to persistence of the SARS-CoV-2 Spike protein within cells, tissues, and
organs. Those vaccinated have been additionally loaded with Spike, so may have
even a worse course with prolonged symptoms including fatigue, lethargy, brain
fog, muscle loss, skin and hair changes, sleeplessness, and effort intolerance.
The magnitude of the problem has driven an all-encompassing search for
management strategies to resolve the syndrome(s).
Hope is on the
horizon with a preprint paper published by Halma et al summarizing the
prescription drug and over-the-counter candidates for therapy. In my practice, I
stylize the approach based on the patient and how recent the COVID-19 infection
was in their history. If there are lingering signs of infection, then a course
of full dose ivermectin can be considered. Aspirin is reasonable given increased
rates of heart attack and stroke after the illness. I have found the colchicine
appears to have an important role in pleurodynia or chest wall discomfort.
Additionally it is used with corticosteroids in vaccine-induced myopericarditis.
Low-dose naltrexone has been reported to ameliorate fatigue and inanition.
Metformin has supportive data and would be appropriate in pre-diabetes and those
with diabetes mellitus.
Halma, M.T.; Plothe, C.; Lawrie, T. Strategies for the
Management of Spike Protein-Related Pathology. Preprints 2023,
2023030344. https://doi.org/10.20944/preprints202303.0344.v1.
From the OTC list, I have found nattokinase, the Japanese product derived
from natto (a traditionalJapanese food made from whole soybeans that have been fermented with Bacillus subtilis var. natto.) to be the most compelling and scientifically supported approach to
clear Spike protein out of the body via proteolytic degradation. A host of
cellular protective, anti-oxidant approaches are listed with vitamin C and
NAC being readily available and widely used.
Nattokinase and Spike Protein
Tanikawa et al. examined the effect of nattokinase on the spike protein of SARS-CoV-2. In
the first experiment, they demonstrated that spike was degraded in a time
and dose-dependent manner in a cell lysate preparation that could be
analogous to a vaccine recipient. The second experiment demonstrated that
nattokinase degraded the spike protein in SARS-CoV-2 infected cells. This
was reproduced in a similar study done by Oba and colleagues in 2021.
Tanikawa T, Kiba Y, Yu J, Hsu K, Chen S, Ishii A, Yokogawa T, Suzuki R,
Inoue Y, Kitamura M. Degradative Effect of Nattokinase on Spike Protein of
SARS-CoV-2. Molecules. 2022 Aug 24;27(17):5405. doi:
10.3390/molecules27175405. PMID: 36080170; PMCID: PMC9458005.
Nattokinase is dosed in fibrinolytic units (FU) per gram and can vary
according to purity. Kurosawa and colleagues have shown in humans that after
a single oral dose of 2000 FU D-dimer concentrations at six, and
eight hours, and blood fibrin/fibrinogen degradation products at four hours
after administration elevated significantly (p < 0.05, respectively).
Thus
an empiric starting dose could be 2000 FU twice a day. Full pharmacokinetic
and pharmacodynamic studies have not been completed, but several years of
market use as an over-the-counter supplement suggests nattokinase is safe
with the main caveat being excessive bleeding and cautions with concurrent
antiplatelet and anticoagulant drugs.
Ivermectin and Spike Protein
Former NIH researcher David Scheim, PhD, early in the pandemic proposed that
SARS-CoV-2 Spike protein was acting like a grappling hook pulling together
circulating red blood cells (RBSc) into long chains and clumps in a process
called hemagglutination (HA). This explained why the red blood cells could
not carry oxygen normally and was congruent with the finding of micro blood
clots in the lungs. Recently, Boschi et al have provided additional support
for this mechanism (source).
According to the authors: “Ivermectin blocked HA when
added to RBCs prior to spike protein and reversed HA when added
afterwards.”
In another spectacular publication, Stone et al,
describes the prompt improvement of oxygenation in patients with ivermectin
(source).
The published oxygenation curves from multiple studies clearly
show this physiological effect of ivermectin occurs so rapidly, it must be
explained by a direct anti-Spike protein effect of ivermectin. An
anonymous video of a critically ill man
demonstrates the very effect that Scheim, Stone, Hazan, and Babalola have
described in the Figure above. So for the next critically ill patient with
COVID-19, if the opportunity presents itself, push for the administration of
ivermectin. This is the only published therapy for COVID-19 that improves
oxygen saturation while the patient mounts a recovery. As in this man, it
may be the critical factor for a turnaround and a chance to walk out of the
hospital.
Key Takeaway
Patients should push their doctors to refer them to clinical trials, and
when that is not feasible, then empiric therapy can be pursued. It is
important to realize that in the absence of completed large randomized
placebo controlled randomized trials, which are easily 5 or more years away
in the future, no therapeutic claims can be made. In the meantime we must be
perceptive as patients and open-minded as clinicians to come up with
reasonable approaches that can be used to help those sick now with
post-COVID syndromes.
Though there are many long haulers treatment protocols out there, we
consider and recommend the I-Recover protocol as one of the best.
Given the lack of clinical trials of long-haul COVID-19 syndrome,
these recommendations are based on the abnormal changes within the
body associated with the COVID-19 disease and post viral illnesses
along with the collective experience of FLCCC members.
This protocol has also been used to treat post-vaccine inflammatory
syndromes with similar success. As with all FLCCC Alliance protocols,
the components, doses, and durations will evolve as more clinical data
accumulates.
Due to the marked overlap between long COVID and post-vaccine syndrome,
please refer to the I-RECOVER Post-Vaccine Treatment protocol for detailed treatment strategies.
The Wellness Company's acclaimed Spike Support Formula contains scientifically-researched
ingredients, including nattokinase, black seed oil, green tea extract
and selenium.
These ingredients are known for their ability
to dissolve spike protein, prevent it from binding to cells, and
repair tissue.
Recommended to maintain daily health for
anyone exposed to COVID, vaccines, or shedding – and may help your
body repair itself and remain at optimal health.
Where to buy Spike Support Formula: Spike Support Formula is available on The Wellness
Company's website. Here is the link: Spike Support Formula (Long Haul Formula)
Note: To get 10% OFF, please use this coupon code: ONEDAYMD
Here are the top 10 pharmaceutical companies as of 2025, updated based on second quarter 2025 revenue data. AstraZeneca, Novartis and Vertex each posted 12% sales increases, offering more evidence of their upward trajectories in recent years. Credit: fiercepharma.com Only one of the top 10 drugmakers, Eli Lilly, is expected to achieve a double-digit revenue increase by the end of 2025. Eli Lilly is projecting a robust growth of around 32% in 2025 compared to 2024, driven by strong sales of its diabetes and weight-loss drugs such as Mounjaro and Zepbound, with full-year revenue guidance between $58 billion and $61 billion ( 1 , 2 , 3 ). Aug 1, 2025 Update: @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) In contrast, m...
Here are the top 10 ETF picks for September 2025, along with insights on whether they are worth considering for investment right now. This list blends global equity leaders, sector specialists in defense and metals, and broad market trackers—balancing momentum with diversification and risk management. We’ve ranked the 10 ETF picks for September 2025 based on their year-to-date (YTD) performance and Assets Under Management (AUM) as of September 2025, using available data from the provided references and general market insights. Since precise YTD performance and AUM figures for some ETFs (e.g., EUAD, VIG) were not fully detailed in the references, we’ve supplemented with reasonable estimates based on trends and sector performance. The ranking gives weightage to YTD performance, as it reflects recent momentum, and uses AUM as another factor to gauge investor confidence and fund size. Ranking Methodology YTD Performance: Based on reported or estimated returns for 2025 (as of September 202...
Here are the top 10 pharmaceutical companies by market cap as of September 2025. The pharmaceutical industry remains robust amid evolving market dynamics, driven by innovation, strategic expansions, and shifting healthcare policies. This mid-2025 update integrates the first half's (H1) financial results to provide readers with a clear snapshot of leading companies’ performance and trajectory. Updates: Aug 1, 2025 Update: @POTUS sent letters to 17 drug manufacturers outlining steps they must take to bring down prescription drug prices. ( source ) Top 10 Pharmaceutical Companies by Revenue in 2025 (August Edition) In contrast, most of the other top 10 pharmaceutical companies are expected to see more moderate revenue growth, generally in the range of 6% to 9% by the end of 2025. This reflects steady but less dramatic expansion compared to Eli Lilly’s exceptional performance ( 4 ). Source: CompaniesMarketCap.com ...
Gold and silver ETFs have shown strong performance in 2025, surpassing the S&P 500 amid inflation concerns, geopolitical tensions, and central bank buying. This article updates the best-performing gold and silver ETFs based on recent data, including 1-year returns, assets under management (AUM), expense ratios, and key notes, evaluating their pros, cons, and attractiveness in the current market.The best gold and silver ETFs of 2025 are noted for exceptional performance, low expense ratios, and reliable tracking of precious metals’ prices. Returns have adjusted slightly since late August due to recent price movements, but momentum remains strong with gold and silver near record highs. Here are the top options across global and key regional markets as of September 2025: Best Gold ETFs of 2025 VanEck Gold Miners ETF (GDX) YTD Performance: +80–115% (reported range for September 2025) ( TradingView ) AUM: ~$16.5B (estimated, based on historical size and 2025 inflows) Rationa...
As the cryptocurrency market matures in 2025, XRP ETFs have emerged as essential instruments for investors seeking regulated and accessible exposure to this dynamic digital asset. With a growing variety of futures-based and physically backed spot ETFs now available across major markets like the U.S., Canada, and Europe, understanding the nuances of these products—including their fee structures, holdings, and performance—is crucial for making informed investment decisions. This article highlights the top XRP ETFs to watch in 2025, providing deep insights into their dominating holdings, low fees, and recent market impact, all organized in a clear list format for easy navigation. Whether you are a long-term investor or an active trader, this guide will help you identify opportunities and risks in the evolving XRP ETF landscape. 1. Leading XRP ETFs in 2025 ProShares Ultra XRP ETF (UXRP) Type: 2x leveraged futures-based ETF listed in the U.S. Launched: July 18, 2025 Key Features...
The best artificial intelligence (AI) stocks to watch and potentially invest in for 2025 include a mix of well-established tech giants and high-growth specialized companies. Below is a brief overview of the state of AI, followed by a list of AI stocks that look promising for 2025. State Of Artificial Intelligence In 2025 A McKinsey report characterizes 2023 as the year "the world discovered generative AI (gen AI)." 2024 is when businesses began realizing value from using gen AI. The rising adoption has sparked extreme demand for AI-capable computing power. Data centers, in turn, invested billions in hardware and software for powering, developing and training AI applications. In 2025, companies like OpenAI will look to move AI's capabilities into increasingly complex tasks. Use cases for AI will expand across industries and into the personal computing space. Organizations that have invested in AI will attempt to quantify the business value of those investments....
Based on the most recent 2025 revenue data, here are the top 10 food companies ranked by revenue: Top 10 Food Companies by Revenue (2025) 1. Nestlé (Switzerland) Revenue: $101.54 billion Key Brands: Nescafe, KitKat, Maggi, Purina, Waters Notes: World's largest food company, with a diverse portfolio including bottled water, coffee, frozen foods, and nutrition products. Nestlé Health Science (NHSc), a subsidiary of Nestlé, owns a variety of supplement brands. Some of the most notable ones include: Garden of Life, Vital Proteins, Pure Encapsulations, Wobenzym, Douglas Laboratories, Persona Nutrition, Genestra, Orthica, Minami, AOV, Klean Athlete, Nature's Bounty, Solgar, Osteo Bi-Flex, and Sundown. 2. Ahold Delhaize (Netherlands) Revenue: $96.22 billion Notes: Major global food retailer and distributor. 3. PepsiCo (USA) Revenue: $91.52 billion Key Brands: Pepsi, Lay's, Gatorade, Tropi...
As of 2025, the Bitcoin ETF landscape is dominated by a mix of spot Bitcoin ETFs offering direct exposure to the cryptocurrency and Bitcoin futures strategy ETFs that provide exposure through futures contracts. The top Bitcoin ETFs expected to dominate based on holdings and fees reflect a balance between large assets under management (AUM), competitive expense ratios, and investor preferences for spot versus futures exposure. What Is a Spot Bitcoin ETF? Spot Bitcoin ETFs, which first began trading on U.S. exchanges Jan. 11, 2024, are exchange-traded funds that track the price of Bitcoin by directly holding the cryptocurrency itself, unlike the futures-based Bitcoin ETFs that have traded on exchanges since 2021. When an investor buys shares of a spot Bitcoin ETF, they are buying a portion of the Bitcoin held by the fund. Thus, a spot Bitcoin fund works in a similar way as a physically backed gold ETF . How to Choose the Best Spot Bitcoin ETF Choosing the...
Here are the top 10 healthcare companies by revenue as of 2024-2025, primarily based on trailing twelve-month (TTM) and fiscal year 2024 revenue data from multiple sources: 1. UnitedHealth Group Inc. Revenue: Approximately $400 billion Description: A leading health insurance company providing data analytics, consulting, and pharmacy care services. Market Capitalisation: $275.8 billion (as of July 2025) Market: NYSE, USA ( 1 , 2 , 4 ) 2. CVS Health Corp. Revenue: Around $361 billion to $373 billion Description: A major pharmacy benefits manager and health services provider. Market Capitalisation: $81.9 billion (as of July 2025) Market: NYSE, USA ( 1 , 2 , 4 ) 3. McKesson Corp. Revenue: About $309 billion to $359 billion Description: A global pharmaceutical distribution and healthcare services company. Market: NYSE, USA ( 1 , 2 , 4 ) 4. Cencora (formerly AmerisourceBergen) Revenue: Approximately $294 billion to $310 billion Description: A pharmaceutical...
As we enter the latter half of 2025, the technology sector continues to dominate global markets, driven by breakthroughs in artificial intelligence (AI), semiconductors, robotics, and cloud computing. With the S&P 500's tech component accounting for over 34% of the index and the Nasdaq-100 even more heavily weighted toward innovation-driven companies, tech and innovation ETFs offer investors a streamlined way to capitalize on these trends. These exchange-traded funds (ETFs) provide diversified exposure to high-growth areas without the need to pick individual stocks, reducing some of the inherent risks while maintaining potential for substantial returns. This comprehensive guide explores the current market landscape, key selection criteria for ETFs, top picks for 2025, portfolio-building strategies, associated risks, and forward-looking forecasts. Whether you're a beginner investor or a seasoned portfolio manager, this resource will help you navigate the evolving world of te...
Comments